The MSBase registry: Informing clinical practice

T Kalincik; H Butzkueven

Journal article

The MSBase registry: Informing clinical practice

T Kalincik, H Butzkueven

Multiple Sclerosis Journal | SAGE PUBLICATIONS LTD | Published : 2019

DOI: 10.1177/1352458519848965

Abstract

Over the last decade, clinical registries have significantly contributed to the pool of evidence that supports management decisions in patients with multiple sclerosis. Being the largest international registry of multiple sclerosis and neuroimmunological disorders, MSBase collects demographic, clinical and limited paraclinical information from patients managed in different regions and under various circumstances. In this review, we will provide an overview of its published output, with focus on the information with impact on the management of multiple sclerosis.

University of Melbourne Researchers

Tomas Kalincik Author

Related Projects (5)

SELECTING OPTIMAL TREATMENT FOR PATIENTS WITH MULTIPLE SCLEROSIS

Multiple sclerosis is the most common cause of neurological disability among young people. With the increasing choice of therapies, the goal..

TREATING PROGRESSIVE MULTIPLE SCLEROSIS

While there are numerous therapies for relapsing-remitting multiple sclerosis (MS), therapy for progressive MS remains elusive. This project..

PRECISION TREATMENT FOR MULTIPLE SCLEROSIS: MAXIMISING THE EFFECT OF IMMUNOMODULATORY THERAPY

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

BIOMARKERS TO PREVENT DISABILITY IN MULTIPLE SCLEROSIS

Response to therapy varies greatly among patients with multiple sclerosis (MS). The current lack of individualised MS therapy may lead to su..

PRECISION THERAPY FOR NEUROLOGICAL DISEASES

Multiple sclerosis is the most common cause of neurological disability among young adults. The patients’ individual response to therapy is h..

Grants

Awarded by Merck

Funding Acknowledgements

The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: The work completed in MSBase and reported in this review was supported by the National Health and Medical Research Council (grants 1083539, 1129189, 1157717, 1071124), Medical Research Future Fund (1140766), Multiple Sclerosis Research Australia, University of Melbourne, Multiple Sclerosis Society (UK), Biogen and MSBase Foundation. The MSBase Foundation is a not-for-profit organisation that receives support from Roche, Merck, Biogen, Novartis, Bayer-Schering, Sanofi-Genzyme and Teva.